Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$16.07 USD
+0.07 (0.41%)
Updated May 20, 2024 11:42 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CHGCY 16.07 +0.07(0.41%)
Will CHGCY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHGCY
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for CHGCY
Chugai Pharmaceutical Co., Ltd. 2024 Q1 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Argenx gains after setback to Roche/Chugai myasthenia gravis therapy
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024